Pharma BD Deal Intelligence
Gilead closed its $1.675B-upfront, ~$2.175B-total buy of Ouro Medicines on June 4, 2026, landing OM336/gamgertamig with FDA Fast Track and Orphan Drug status in AIHA and ITP — but it's still just Phase 1/2, with Lakefront Biotherapeutics doing the actual development legwork.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos. Gilead is acquiring Ouro Medicines for approximately $2.175 billion,…
Gilead to acquire immunology biotech, offers lifeline to Galapagos. Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease…
Gilead Sciences and Lakefront complete acquisition of Ouro Medicines to further expand inflammation pipeline. Lakefront is responsible for the ongoing and…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Gilead completed its acquisition of privately held Ouro Medicines on June 4, 2026 (announced March 23, 2026), paying $1.675B upfront plus up to $500M in contingent milestones (~$2.175B total) for BCMAxCD3 T-cell engager OM336/gamgertamig, in Phase 1/2 for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) and carrying FDA Fast Track and Orphan Drug designations in both. Under a concurrent collaboration, Lakefront Biotherapeutics (the former Galapagos NV, which rebranded effective May 8, 2026) absorbed Ouro's R&D team and runs the ongoing Phase 1/2 studies; Gilead leads registrational and later-stage development and commercialization ex-Greater China. The two companies split the upfront and milestone payments equally, and Lakefront receives tiered 20-23% royalties on gamgertamig net sales. Registrational studies are expected to begin as early as 2027, extending Gilead's inflammation franchise.
38K US cases/yr · ~70-80% Share of primary AIHA cases classified as warm AIHA (IgG-mediated)
Warm autoimmune hemolytic anemia (wAIHA) is a rare acquired autoimmune disorder in which IgG autoantibodies (occasionally IgA/IgM) bind red blood cell surface antigens at body temperature, triggering complement activation and extravascular hemolysis predominantly in the spleen. Patients present with fatigue, pallor, jaundice, splenomegaly, and laboratory evidence of hemolysis (elevated LDH, indirect bilirubin, reticulocytosis, positive direct antiglobulin test). US incidence is approximately 1.4-6.6 per 100,000 persons per year, with a point prevalence of 11.6-17.3 per 100,000; estimated 2023 US prevalent population was approximately 38,000-57,000 patients. Warm AIHA accounts for approximately 70-80% of primary AIHA cases. Current first-line treatment is corticosteroids, with rituximab as second-line; splenectomy is reserved for refractory disease. Many patients relapse or remain steroid-dependent, and the only FDA-approved AIHA-specific therapy is SYK inhibitor fostamatinib (post-2022 approval for chronic ITP, used off-label in AIHA). Deep B-cell and plasma-cell depletion via BCMA/CD3 bispecifics addresses plasma-cell-driven autoantibody persistence.
AIHA has no approved disease-specific biologic; treatment is largely repurposed. Standard care: corticosteroids first-line, rituximab (anti-CD20) second-line, splenectomy, cyclosporine, mycophenolate, or IVIG in refractory cases. Emerging therapies competing with OM336/gamgertamig include: Rigel's fostamatinib (Tavalisse, SYK inhibitor, Phase 3 FORWARD in wAIHA), Novartis' iptacopan (Fabhalta, factor B inhibitor, Phase 3 in cold agglutinin disease and wAIHA), Sanofi's sutimlimab (Enjaymo, C1s inhibitor, approved for CAD 2022 at $8,000/month), Bioverativ/Sanofi's BIVV020, and anti-CD38 daratumumab (Darzalex, plasma-cell depletion, investigator-initiated studies). In immune thrombocytopenia (ITP), approved agents include TPO-RAs romiplostim (Nplate), eltrombopag (Promacta), avatrombopag (Doptelet), SYK inhibitor fostamatinib, and BTK inhibitor rilzabrutinib (Sanofi, FDA-approved 2024). OM336 differentiates by targeting plasma-cell/B-cell depletion with a T-cell engager mechanism producing deeper, potentially drug-free remissions.
20K US cases/yr · $2.5B Global ITP therapeutics market (2024, TPO-RAs dominant) · 30-40% Share of chronic ITP patients refractory to or intolerant of TPO-RAs (unmet need)
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by isolated thrombocytopenia (platelets <100 x 10^9/L) due to IgG autoantibody-mediated platelet destruction and impaired platelet production. Clinical manifestations range from asymptomatic thrombocytopenia to petechiae, mucocutaneous bleeding, and rare life-threatening hemorrhage. US annual incidence is approximately 6.1 per 100,000 (higher in children ages 0-4 and adults ≥65), and prevalence is approximately 9.5-12 per 100,000; roughly 20,000 new US diagnoses per year. Primary ITP accounts for most adult cases, while secondary ITP is associated with lupus, HIV, HCV, or lymphoproliferative disease. First-line treatment is corticosteroids, IVIG, or anti-D; second-line options include thrombopoietin receptor agonists (TPO-RAs) such as eltrombopag (Promacta), romiplostim (Nplate), and avatrombopag (Doptelet), plus rituximab, splenectomy, the SYK inhibitor fostamatinib (Tavalisse), and BTK inhibitor rilzabrutinib (Wayrilz, Sanofi, approved 2024). Refractory and relapsing chronic ITP remains a significant unmet need and the target setting for deeper immune-reset therapies such as BCMAxCD3 T-cell engagers.
ITP has an established but limited treatment landscape. First-line is corticosteroids, IVIG, or anti-D immune globulin. Second-line thrombopoietin receptor agonists (TPO-RAs) dominate commercial use: eltrombopag (Promacta, Novartis, ~$1.6B 2024 revenue), romiplostim (Nplate, Amgen), and avatrombopag (Doptelet, Sobi). Other approved options include the SYK inhibitor fostamatinib (Tavalisse, Rigel), and BTK inhibitor rilzabrutinib (Wayrilz, Sanofi, approved 2024). Rituximab is used off-label for B-cell depletion. Investigational competitors to OM336 in the chronic refractory ITP setting include: Argenx's efgartigimod (FcRn inhibitor, Phase 3 ADVANCE-positive, filed), Momenta/J&J's nipocalimab (FcRn inhibitor, Phase 3), CSL's HMPL-523/CSL312 garadacimab, and Gilead's own pipeline BTK inhibitor programs. OM336's BCMAxCD3 TCE mechanism is differentiated from autoantibody-clearance (FcRn) and signaling-pathway (BTK/SYK) approaches in that it targets the autoantibody-producing plasma cell directly.
Acquisition closed June 4, 2026. $1.675B upfront + up to $500M milestones. Lakefront Biotherapeutics (formerly Galapagos) collaborates on gamgertamig (OM336), running Phase 1/2 while Gilead leads registrational development; Lakefront earns 20-23% royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Ouro Medicines, Inc. (this deal) | 2026 | $2.2B | — |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2026 deals · Gilead Sciences Inc. deals · Hematology deals